This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Stocks to Buy Ahead of Q2 Earnings Results Next Week
by Nalak Das
Five companies will report second-quarter 2022 earnings results next week. These are: EQT, MEDP, CR, HES and ZION.
Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums
by Zacks Equity Research
Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.
Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.
Icon PLC (ICLR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights Medpace, Texas Pacific Land and Delek
by Zacks Equity Research
Medpace, Texas Pacific Land and Delek have been highlighted in this Screen of the Week article.
Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in operating expenses.
Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include Medpace, Texas Pacific Land and Delek US Holdings
by Zacks Equity Research
Medpace, Texas Pacific Land and Delek US Holdings are part of Zacks Screen of the week article.
3 Top Stocks to Bet on for Superb Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like Medpace (MEDP), Texas Pacific Land (TPL) & Delek US Holdings (DK) at the moment for solid earnings growth.
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
by Zacks Equity Research
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
Strength Seen in NovoCure (NVCR): Can Its 8% Jump Turn into More Strength?
by Zacks Equity Research
NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.
Walgreens (WBA) to Offer Health Services to Ohio Medicaid Members
by Zacks Equity Research
Walgreens' (WBA) subsidiary teams up with Buckeye Health Plan to provide wellness services through Walgreens Health Corner locations in Ohio.
National Vision (EYE) Gains on Volume Growth Amid Margin Woes
by Zacks Equity Research
National Vision (EYE) plans to continue executing its core growth initiatives and further investing in strengthening competitive advantages.
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
by Zacks Equity Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
Charles River (CRL) Prospers Internationally Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Bruker (BRKR) BSI & BEST Arms Drive Growth Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Walgreens (WBA) Starts COVID Jabs for 3-Year Olds & Above
by Zacks Equity Research
Walgreens Boots (WBA) continues to serve communities with COVID testing and vaccinations to fight the pandemic.
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Henry Schein (HSIC) Global Dental Arm Rebounds Amid Cost Woes
by Zacks Equity Research
Henry Schein's (HSIC) widespread network and channel mix along with favorable long-term trends in the dental business look encouraging.